Últimas noticias sobre Immatics (NASDAQ:IMTX) Bolsa

Immatics

Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.

Immatics NV

WIIM

AXIL

AXIL Brands shares are trading higher. The company reported Q1 financial results.

GAUZ

Gauzy shares are trading higher after the company announced its advanced driver assistance system (ADAS) will fully replace the traditional side mirrors for the buses of the Capital District Transportation Authority of New York. The company estimates cumulative revenue for its commercial camera monitor system (CMS) ADAS will surpass $100 million by the end of 2025.

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk has dreamed for years of having vehicles that don't require a driver and can take a passenger from one place to another. On Thursday, Musk's vision could be realized with the likely unveiling of <a href="https://www.benzinga.com/trading-ideas/24/10/41274987/how-to-watch-tesla-robotaxi-day-live-elon-musks-autonomous-vehicle-event-is-here">the Tesla Robotaxi.</a>
However, a new survey finds that when it comes to demand and consumer trust, the robot axis might not be ready for mass adoption.
What Happened: A new J.D. Power survey of consumers tests the experience and ratings of passengers who have taken a ride in <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41212796/tesla-robotaxi-day-preview-move-over-autonomous-vehicles-analyst-says-this-positive">an autonomous vehicle.</a>
The 2024 U.S. Robotaxi Experience Study <a href="https://www.jdpower.com/business/press-releases/2024-us-robotaxi-experience-study">found </a>that consumers had an average level of satisfaction of 8.53 on a 10-point scale.
The study, which took place in August, is based on the five categories of comfort and convenience, initiating the ride, riding in the vehicle, service availability and cost, and vehicle technology. Of the five categories, technology scored the highest.
Consumers who rode in a robotaxi had a 76% consumer confidence score for a fully automated, self-driving vehicle. While that score is relatively high, the consumer confidence score of people for fully automated, self-driving vehicles who have not ridden in a robotaxi was only 20%.
When asked to describe their ideal robotaxi service, respondents prioritized safety, with 78% selecting it as the most important factor, followed by reliability at 71% and trustworthiness at 66%.
One of the most important consumer requests in the survey was for the robotaxi to offer an emergency button to connect to local emergency services. Other requests were for the ability to select vehicles based on safety features and having the route set beforehand.
Companies mentioned in the report, which had their vehicles tested, include:
<ul>
<li>Cruise, which is majority owned by General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>)</li>
<li>May Mobility</li>
<li>Motional, which is a joint venture between Hyundai (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HYMLF#OTC">HYMLF</a>) and Aptiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>)</li>
<li>Waymo, a subsidiary of Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)</li>
<li>Zoox, a subsidiary of Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</li>
</ul>
The study occurred in the five markets of Dallas, Las Vegas, Los Angeles, Phoenix and San Francisco.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul>
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Why It's Important: The study finds relatively high trust and satisfaction ratings for consumers who experience a robotaxi in some of the largest cities that have approved or are testing the technology.
Another takeaway from the report is that even living in a city with robotaxis and higher consumer awareness can improve trust in the technology. The study found that consumer confidence was 34% for people who had not ridden in a robotaxi and lived in one of the cities with robotaxis in operation.
"The robotaxi segment is still anyone's game, given that most people are not familiar with robotaxi brands and haven't formed a clear associative imagery," J.D. Power Senior Director of user experience benchmarking and technology Kathleen Rizk said.
Rizk added that the companies with robotaxis need to "look beyond their deployment markets and find ways to educate and build trust with all consumers."
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/education/24/10/41166723/how-many-evs-has-tesla-delivered-produced-each-quarter-a-look-at-the-results-since-2019" target="_blank" rel="noreferrer noopener">How Many EVs Has Tesla Delivered, Produced Each Quarter? A Look At The Results Since 2019</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Tech

Trading Ideas

AMZN

APTV

GOOG

GOOGL

HYMLF

TLSA

TSLA

Elon Musk May Unveil Tesla's Robotaxi, But Consumers Respond With 'Ehhh,' New Study Reveals Skepticism, Need For Trust-Building

BNGO

Bionano Genomics shares are trading lower after the company cut its preliminary Q3 revenue guidance.

JP Morgan analyst Jimmy Bhullar maintains Allstate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) with a Overweight and raises the price target from $205 to $207.

News

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Allstate, Raises Price Target to $207

SPCB

SuperCom shares are trading higher after the company announced it and its partner were awarded a 5-year national electronic monitoring contract with the Israel Prison Service Agency.

Editor's Note: Today you're getting a sneak peek at "Under The Radar" – a weekly email showcasing profit opportunities no one else is talking about, exclusive to members of Benzinga Edge. To get "Under The Radar" in your inbox every Tuesday, as well as a slew of other trade ideas, analysis, and investing tools, <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9spmirebz65&amp;utm_source=RD-1010">join Benzinga Edge here</a>.
There are lots of stories and discussions about insider buying that hit the internet every day. Most appear to have been written by people whose research into corporate insiders&#8217; buying and selling activities involves reading the book jacket blurbs on a book containing a chapter on insider activity.
Some insider buying matters. Some carry very little helpful information.
Although you will see breathless stories suggesting a likely stock market apocalypse because an insider is selling shares of a current market darling, the truth is that such sales are almost always meaningless.
A large institution buying more small company shares will often appear on the tape as a big insider buy. Still, this information is useless as an indicator of future returns.
Most option exercises and stock grants are worthless in terms of predictive value.
Knowing which insider purchases contain valuable information is critical if you use insider activity as a basis for investment or trading activities.
See, there's one group of insiders that consistently win when they open their checkbooks and buy their company&#8217;s stock on the open market.
Here's how to find them.
I am talking about C-suite executives. These are the folks involved in the big decisions about the company who want to see the daily operations and results.
They have a significant information advantage, not just over the public but also over other executives and board members.
The higher up on the food chain you are, the better your chances of making big money on your insider trades. The CEO and CFO have the highest probability of success.
Of these two, the CEO does not have the edge. The CEO sees everything that happens as planned for the company. The CFO lives with the numbers and cash flows all day, every day, and understands how every decision will impact the company&#8217;s profits and financial conditions.
Historically, that edge has allowed the CFO to earn very high returns when they make an open market purchase of their company stock.
Here at Under the Radar, we have spent considerable time reading studies and crunching data related to insider activity. One of the biggest lessons is that intelligent investors pay attention when a CFO whips out their checkbook.
The stock market has been very strong this year, so there has been far more insider selling than buying activity.
Insiders tend to be bargain hunters, and bargains have been hard to find recently.
Recently, we have seen two CFO buys that are worth our attention.
CFO Andrew Williams of Epsilon Energy (EPSN) has recently been making open-market six-figure purchases of his company.
While he bought his shares a little below the current market price, the low level of oil and gas in the third quarter is likely to lead to an earnings disappointment when the company reports its third-quarter results.
Epsilon is positioned to see a huge long-term profit increase due to increased natural gas demand over the next several years.
Recently, the CFO had done some financial modeling and understands, as we do, that the impact of rising natural gas prices on Epsilon&#8217;s bottom line should result in a dramatically higher stock price.
While the real opportunity in shares of Epsilon is the potential for several times your purchase price over the next several years, it doesn&#8217;t hurt that the company pays a generous dividend.
At the current price, Epsilon shares are yielding over 4%.
I know nothing about biotechnology or pharmaceutical development; I doubt that most Experts on the Internet have much knowledge of the drug approval process and which drugs will hit and which ones will not.
However, the C-suite executives have a pretty good idea of how it all works and the potential for their stock if they gain approval or cut a deal with a bigger company.
More than anyone, the CFO knows exactly what will happen to the bottom line in the case of these wildly positive developments.
When the Chief Financial Officer decides it is worth investing six figures in the stock of the company they oversee, it is worth paying attention.
Relmada Therapeutics Inc. (RLMD) is developing new drugs to treat central nervous system diseases. The company is also researching ways to use low-dose psilocybin as a treatment for metabolic diseases and is conducting other drug trials.
My knowledge of psilocybin as a treatment for anything is limited to a handful of Grateful Dead concerts in the 1970s.
CFO Maged Shenouda knows more about the drugs the company is developing and what it will do for the bottom line and stock price than I ever will.
He has been making open market purchases of the stock regularly this year, with the latest six-figure open market buys taking place just a few weeks ago.
He is not the only one buying. CEO Sergio is also making consistent large purchases of the stock.
Here is where it gets interesting.
Without much fanfare, Jefferies, the brokerage and research firm, recently upgraded the stock to a buy, saying that the current drug in Phase 3 trials has a chance of being a huge success for the company. Analyst Andrew Tsai raised his price target to $14.
Both stocks have remained under the radar of Main Street media and most of Wall Street.
If the CFOs are correct, both stocks have the potential for returns that are several times the current stock price.
Every Tuesday, Benzinga Edge members get a weekly "Under The Radar" story like this one, in addition to other trade ideas, investment analysis, and much more throughout the week. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9spmirebz65&amp;utm_source=RD-1010">Join Benzinga Edge here.</a>
Image generated using DALL-E.

Opinion

How To Find The Insider Trades That Consistently Outperform The Market – Under The Radar

Investors with a lot of money to spend have taken a bullish stance on Cleanspark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CLSK, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Cleanspark.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 25%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $211,500, and 6 are calls, for a total amount of $500,495.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $6.0 to $25.0 for Cleanspark over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Cleanspark's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Cleanspark's whale activity within a strike price range from $6.0 to $25.0 in the last 30 days. 
<h3>Cleanspark 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728587031_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLSK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$3.05</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$20.00</td>
<td>$288.9K</td>
<td>10.2K</td>
<td>997</td>
</tr>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$17.25</td>
<td>$16.8</td>
<td>$17.25</td>
<td>$25.00</td>
<td>$172.5K</td>
<td>2.5K</td>
<td>451</td>
</tr>
<tr>
<td>CLSK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/25/24</td>
<td>$0.26</td>
<td>$0.24</td>
<td>$0.25</td>
<td>$10.00</td>
<td>$74.6K</td>
<td>1.5K</td>
<td>3.1K</td>
</tr>
<tr>
<td>CLSK</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$2.08</td>
<td>$2.01</td>
<td>$2.05</td>
<td>$9.00</td>
<td>$40.9K</td>
<td>3.7K</td>
<td>225</td>
</tr>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$2.61</td>
<td>$2.59</td>
<td>$2.6</td>
<td>$10.00</td>
<td>$39.0K</td>
<td>3.2K</td>
<td>227</td>
</tr>
</tbody>
</table>

<h3>About Cleanspark</h3>
Cleanspark Inc is a bitcoin mining company. Through CleanSpark, Inc., and the Company's wholly owned subsidiaries, the company mines bitcoin. The company entered the bitcoin mining industry through its acquisition of ATL. Bitcoin mining is the sole reportable segment of the company.
After a thorough review of the options trading surrounding Cleanspark, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Cleanspark</h3>
<ul>
<li>With a trading volume of 9,485,958, the price of CLSK is down by -2.16%, reaching $8.67.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 50 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Cleanspark</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $24.25.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from HC Wainwright &amp; Co. has revised its rating downward to Buy, adjusting the price target to $27. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $23. 
&#x2A; Reflecting concerns, an analyst from HC Wainwright &amp; Co. lowers its rating to Buy with a new price target of $27. 
&#x2A; An analyst from Macquarie has revised its rating downward to Outperform, adjusting the price target to $20. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cleanspark options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

CLSK

A Closer Look at Cleanspark's Options Market Dynamics

Investors with a lot of money to spend have taken a bullish stance on General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 14 uncommon options trades for General Motors.
This isn't normal.
The overall sentiment of these big-money traders is split between 42% bullish and 42%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $243,598, and 11 are calls, for a total amount of $1,764,752.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $30.0 to $60.0 for General Motors over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for General Motors options trades today is 7054.08 with a total volume of 15,545.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for General Motors's big money trades within a strike price range of $30.0 to $60.0 over the last 30 days.
<h3>General Motors Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728587026_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.86</td>
<td>$1.67</td>
<td>$1.74</td>
<td>$60.00</td>
<td>$870.0K</td>
<td>18.1K</td>
<td>5.0K</td>
</tr>
<tr>
<td>GM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$0.89</td>
<td>$0.85</td>
<td>$0.87</td>
<td>$48.00</td>
<td>$174.0K</td>
<td>7.1K</td>
<td>2.0K</td>
</tr>
<tr>
<td>GM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$1.51</td>
<td>$1.46</td>
<td>$1.47</td>
<td>$47.00</td>
<td>$147.0K</td>
<td>10.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>GM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$1.36</td>
<td>$1.31</td>
<td>$1.32</td>
<td>$47.00</td>
<td>$132.0K</td>
<td>10.8K</td>
<td>2.5K</td>
</tr>
<tr>
<td>GM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$1.22</td>
<td>$1.1</td>
<td>$1.11</td>
<td>$30.00</td>
<td>$111.0K</td>
<td>6.9K</td>
<td>1.0K</td>
</tr>
</tbody>
</table>

<h3>About General Motors</h3>
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company regained its us market share leader crown in 2022, after losing it to Toyota due to the chip shortage in 2021. 2023's share was 16.5%. GM's Cruise autonomous vehicle arm has previously done driverless geofenced AV robotaxi services in San Francisco and other cities but stopped in late 2023 after an accident. It restarted service in 2024 but not in California. GM owns over 80% of Cruise. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
After a thorough review of the options trading surrounding General Motors, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>General Motors's Current Market Status</h3>
<ul>
<li>With a trading volume of 5,775,085, the price of GM is down by -0.73%, reaching $47.58.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 12 days from now.</li>
</ul>
<h3>What Analysts Are Saying About General Motors</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $53.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Morgan Stanley lowers its rating to Underweight with a new price target of $42. 
&#x2A; In a cautious move, an analyst from Wedbush downgraded its rating to Outperform, setting a price target of $55. 
&#x2A; An analyst from Bernstein has revised its rating downward to Market Perform, adjusting the price target to $53. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $54. 
&#x2A; An analyst from Goldman Sachs persists with their Buy rating on General Motors, maintaining a target price of $61. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for General Motors with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

This Is What Whales Are Betting On General Motors

High-rolling investors have positioned themselves bullish on Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in SNAP often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 11 options trades for Snap. This is not a typical pattern.
The sentiment among these major traders is split, with 63% bullish and 36% bearish. Among all the options we identified, there was one put, amounting to $51,500, and 10 calls, totaling $949,490.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $5.0 to $15.0 for Snap over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Snap's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Snap's whale activity within a strike price range from $5.0 to $15.0 in the last 30 days. 
<h3>Snap 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728587021_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SNAP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.07</td>
<td>$2.02</td>
<td>$2.02</td>
<td>$15.00</td>
<td>$202.1K</td>
<td>8.4K</td>
<td>1.3K</td>
</tr>
<tr>
<td>SNAP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.06</td>
<td>$2.02</td>
<td>$2.02</td>
<td>$15.00</td>
<td>$202.0K</td>
<td>8.4K</td>
<td>2.3K</td>
</tr>
<tr>
<td>SNAP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$6.75</td>
<td>$6.75</td>
<td>$6.75</td>
<td>$5.00</td>
<td>$195.7K</td>
<td>1.1K</td>
<td>650</td>
</tr>
<tr>
<td>SNAP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$3.1</td>
<td>$3.0</td>
<td>$3.1</td>
<td>$13.00</td>
<td>$89.9K</td>
<td>768</td>
<td>650</td>
</tr>
<tr>
<td>SNAP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$6.75</td>
<td>$6.65</td>
<td>$6.75</td>
<td>$5.00</td>
<td>$67.5K</td>
<td>1.1K</td>
<td>310</td>
</tr>
</tbody>
</table>

<h3>About Snap</h3>
Snap owns one of the most popular social networking apps, Snapchat, claiming more than 400 million daily active users as of the end of 2023. Snap generates nearly all its revenue from advertising. While only about one quarter of users are in North America, the region accounts for about 65% of sales.
After a thorough review of the options trading surrounding Snap, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Snap</h3>
<ul>
<li>With a trading volume of 8,749,623, the price of SNAP is down by -0.6%, reaching $10.62.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 19 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Snap</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $11.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Snap, maintaining a target price of $14. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $8. 
&#x2A; Reflecting concerns, an analyst from B. Riley Securities lowers its rating to Neutral with a new price target of $11. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $8. 
&#x2A; Consistent in their evaluation, an analyst from Deutsche Bank keeps a Buy rating on Snap with a target price of $14. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Snap options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

SNAP

Snap's Options: A Look at What the Big Money is Thinking

JP Morgan analyst Jimmy Bhullar maintains Arch Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) with a Neutral and raises the price target from $108 to $110.

ACGL

JP Morgan Maintains Neutral on Arch Capital Group, Raises Price Target to $110

JP Morgan analyst Jimmy Bhullar maintains Baldwin Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWIN#NASDAQ">BWIN</a>) with a Overweight and raises the price target from $45 to $54.

BWIN

JP Morgan Maintains Overweight on Baldwin Insurance, Raises Price Target to $54

9 analysts have shared their evaluations of Hubbell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Hubbell, revealing an average target of $416.67, a high estimate of $454.00, and a low estimate of $368.00. This upward trend is evident, with the current average reflecting a 4.23% increase from the previous average price target of $399.75.
<img src="https://www.benzinga.com/files/images/story/2024/1728586892_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Hubbell among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$454.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$445.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$400.00</td>
<td>$368.00</td>
</tr>
<tr>
<td>Chris Snyder</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$407.00</td>
<td>-</td>
</tr>
<tr>
<td>Nicole Deblase</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$441.00</td>
<td>$431.00</td>
</tr>
<tr>
<td>Tommy Moll</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$450.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$368.00</td>
<td>$384.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$385.00</td>
<td>$383.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$400.00</td>
<td>$397.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hubbell. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Hubbell compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Hubbell's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Hubbell's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/HUBB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Hubbell analyst ratings.</a>
<h2>Delving into Hubbell's Background</h2>
Hubbell is a diversified conglomerate industrial company that mostly competes in the electrical components market. Its products and services serve vital portions of the U.S. electrical supply chain, including transmission and distribution as well as the commercial, industrial, and residential end markets. The company organizes its business into two segments: Utility Solutions Segment and the Electrical Solutions Segment. It derives maximum revenue from Utility Solutions Segment.
<h3>Understanding the Numbers: Hubbell's Finances</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Hubbell's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 6.34%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Hubbell's net margin is impressive, surpassing industry averages. With a net margin of 14.68%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Hubbell's ROE stands out, surpassing industry averages. With an impressive ROE of 7.13%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Hubbell's ROA excels beyond industry benchmarks, reaching 3.1%. This signifies efficient management of assets and strong financial health.
Debt Management: Hubbell's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.7.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HUBB

Assessing Hubbell: Insights From 9 Financial Analysts

A2Z Cust2Mate Solutions shares are trading higher after the company announced it signed a framework agreement with Trixo for its smart cart solutions to be rolled out in Mexico and Central America.

Across the recent three months, 5 analysts have shared their insights on Root (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $73.4, with a high estimate of $88.00 and a low estimate of $61.00. Observing a downward trend, the current average is 6.85% lower than the prior average price target of $78.80. 
<img src="https://www.benzinga.com/files/images/story/2024/1728586884_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Root among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$64.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Yaron Kinar</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$72.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Tommy McJoynt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Brian Meredith</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$61.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Thomas McJoynt-Griffith</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Root. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Root compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Root's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Root's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ROOT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Root analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Root Better</h2>
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. The company is a direct-to-consumer personal auto insurance, renters insurance and mobile technology company. It generates revenue from the sale of auto insurance policies within the United States.
<h3>Unraveling the Financial Story of Root</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Root's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 286.63%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Root's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -2.7%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Root's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -4.92%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Root's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.53%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Root's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.98, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ROOT

Analyst Scoreboard: 5 Ratings For Root

Hamilton Insurance Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HG#NYSE">HG</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Hamilton Insurance Group, presenting an average target of $22.17, a high estimate of $26.00, and a low estimate of $19.00. This current average reflects an increase of 9.75% from the previous average price target of $20.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1728586868_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Hamilton Insurance Group among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$26.00</td>
<td>-</td>
</tr>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Tommy McJoynt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Matthew Carletti</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Hamilton Insurance Group. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hamilton Insurance Group compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Hamilton Insurance Group's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Hamilton Insurance Group's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Hamilton Insurance Group analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Hamilton Insurance Group: A Closer Look</h2>
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in Lloyd's, Ireland, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
<h3>Understanding the Numbers: Hamilton Insurance Group's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Hamilton Insurance Group's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 62.39%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Hamilton Insurance Group's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 21.83%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Hamilton Insurance Group's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.89%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Hamilton Insurance Group's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.75% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Hamilton Insurance Group's debt-to-equity ratio is below the industry average. With a ratio of 0.07, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Hamilton Insurance Group Stock

Legal

Td Bank Says Will Undertake Balance Sheet Restructuring In Fy25; Will Reduce Assets By About 10%, Which Will Include Managing Down Or Selling Certain Loan Portfolios; Incoming CEO Says " This Is A Difficult Chapter For TD... We Will Make The Necessary Changes To Put The Bank On Stronger Foundation"

In the latest quarter, 5 analysts provided ratings for MPLX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $48.4, along with a high estimate of $51.00 and a low estimate of $45.00. Marking an increase of 3.42%, the current average surpasses the previous average price target of $46.80. 
<img src="https://www.benzinga.com/files/images/story/2024/1728586853_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of MPLX by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Brian Reynolds</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$47.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MPLX. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of MPLX compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of MPLX's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of MPLX's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MPLX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on MPLX analyst ratings.</a>
<h2>Get to Know MPLX Better</h2>
MPLX is a partnership that owns both pipelines and gathering and processing assets with extensive holdings in the Appalachian region. The asset base is made up of pipeline assets dropped down from Marathon Petroleum, its sponsor, and gathering and processing assets from MarkWest, which it acquired in 2015. MPLX also acquired Andeavor Logistics in 2019.
<h3>MPLX's Economic Impact: An Analysis</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Positive Revenue Trend: Examining MPLX's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.53% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Energy sector.
Net Margin: MPLX's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 43.63% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 8.65%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): MPLX's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.13% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: MPLX's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.67.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MPLX

Analyst Scoreboard: 5 Ratings For MPLX

Iron Mountain (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRM#NYSE">IRM</a>) has outperformed the market over the past 5 years by 15.44% on an annualized basis producing an average annual return of 29.43%. Currently, Iron Mountain has a market capitalization of $35.34 billion. 
Buying $1000 In IRM: If an investor had bought $1000 of IRM stock 5 years ago, it would be worth $3,664.31 today based on a price of $120.49 for IRM at the time of writing.
<h3>Iron Mountain's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728586841_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Iron Mountain 5 Years Ago Would Be Worth Today

Cenovus Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVE#NYSE">CVE</a>) has outperformed the market over the past 5 years by 1.84% on an annualized basis producing an average annual return of 15.83%. Currently, Cenovus Energy has a market capitalization of $32.82 billion. 
Buying $1000 In CVE: If an investor had bought $1000 of CVE stock 5 years ago, it would be worth $2,106.76 today based on a price of $17.68 for CVE at the time of writing.
<h3>Cenovus Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728586836_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today

In a report released yesterday, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Immatics (IMTX – Research Report), with a price...

Buy Rating for Immatics: Promising Clinical Trials and Strong Financials Signal Upside Potential

With the rising prevalence of chronic diseases, increasing cell and gene therapies, and rising tech adoption in the biotech industry, the oncology market is booming. Amid this backdrop, investors could consider quality biotech stocks Pyxis Oncology (PYXS), Immatics (IMTX), and Jazz Pharmaceuticals (JAZZ), having significant upside potential. Continue reading... The oncology market is playing an inevitable role worldwide with its latest innovation offering solutions for fatal diseases. Also, the rapidly rising R&amp;D activities and surging investments, coupled with the adoption of cutting-edge technologies are propelling the growth and development of the market.
Given the industry's rosy prospects, it could be wise to invest in fundamentally strong biotech stocks Pyxis Oncology, Inc. (<a href="https://stocknews.com/stock/PYXS/">PYXS</a>), Immatics N.V. (<a href="https://stocknews.com/stock/IMTX/">IMTX</a>), and Jazz Pharmaceuticals plc (<a href="https://stocknews.com/stock/JAZZ/">JAZZ</a>) poised for major upside.
Incidents of patients being affected by cancer is increasing dramatically and is projected to grow through the middle of the century across the globe. Simultaneously, ecosystem engaged in the discovery, developing, and delivering breakthrough therapies in entirely new areas of science is on steep high levels.
These factors are continuously contributing to the <a href="https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2024">breakthroughs in the oncology market and propelling its prospects</a>. Last year, over 25 novel oncology active substances were unveiled worldwide, and more than 2,000 new oncology clinical trials were set in motion, such as cell and gene therapies, antibody-drug conjugates, multispecific antibodies, and radioligand therapies.
The oncology drugs market is expected to reach a projected revenue of $194.10 billion by 2024 worldwide. In comparison to the world, the US continues its dominance over the world in the segment with <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/oncology-drugs/worldwide">oncology drug development and innovation</a>, having numerous breakthrough therapies approved by the FDA and is expected to generate the highest revenue, with $103.90 billion in 2024.
The global oncology drugs market is anticipated to reach $518.25 billion by 2032, exhibiting growth at a notable <a href="https://www.fortunebusinessinsights.com/oncology-drugs-market-103431">CAGR of 11.3%</a>. Factors including the rising prevalence of different type of cancer, increasing new drug launches and product approvals, and growing research activities in the field contribute to the market growth.
Given these favorable market trends, let's look at the fundamentals of the top three <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, beginning with the third choice.
Stock #3: Pyxis Oncology, Inc. (<a href="https://stocknews.com/stock/PYXS/">PYXS</a>)
PYXS is a clinical stage company engaged in the development of therapeutics to treat cancers. The company's lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1, in the Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors.
On August 15, PYXS announced that its PYX-201, an ADC that uniquely targets EDB+FN within the tumor stroma which is PYXS' lead clinical program is being evaluated in an ongoing Phase 1 trial in multiple types of solid tumors. The company expects to announce preliminary data from the Phase 1 trial of PYX-201 in the fall of 2024.
For the six months that ended June 30, 2024, PYXS posted <a href="https://www.investopedia.com/terms/r/revenue.asp">total revenues</a> of $16.15 million, of which its royalty revenues stood at $8.15 million for the same period. The company's total other income, net came in at $5.08 million for the half year.
In addition, the company's cash and cash equivalents were $25.07 million as of June 30, 2024, compared to $9.6 million as of December 31, 2023.
Shares of PYXS have increased 79.7% over the past year to close the last trading session at $3.81. Wall Street analysts expect the stock to hit $8 in the near term, indicating a potential <a href="https://www.tipranks.com/stocks/pyxs/forecast">upside of 110%</a>.
PYXS' robust growth prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has a B grade for Sentiment. Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, PYXS is ranked #90 out of 341 stocks.
<a href="https://stocknews.com/stock/PYXS/">Click here</a> to access additional ratings of PYXS for Stability, Growth, Value, Quality, and Momentum.
Stock #2: Immatics N.V. (<a href="https://stocknews.com/stock/IMTX/">IMTX</a>)
Headquartered in Tübingen, Germany, IMTX is a clinical-stage biopharmaceutical company which focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer. It is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities.
IMTX's revenue has grown at a CAGR of 33.3% over the past three years. The company's tangible book value has increased 72.6% over the same timeframe, while its total assets have improved at a CAGR of 42.5%.
IMTX's revenue from collaboration agreements increased 52.5% from the year-ago value to €49.02 million ($54.77 million) during the six months that ended June 30, 2024. The company's cash and cash equivalents and total assets came in at €158.14 million ($176.69 million) and €626.97 million ($700.51 million) as of June 30, 2024.
Analysts expect IMTX's revenue for the third quarter (ending September 2024) to increase 161.1% year-over-year to $16.55 million. For the fiscal year 2024, the company's revenue is expected to grow 35.6% year-over-year to $79.48 million. Also, the company has topped the consensus EPS estimates in all of the trailing four quarters.
IMTX's shares have gained 36.3% over the past nine months to close the last trading session at $11.49. Wall Street analysts expect the stock to hit $17.33 in the near term, indicating a potential <a href="https://www.tipranks.com/stocks/imtx/forecast">upside of 50.8%</a>.
IMTX's sound fundamentals are reflected in its POWR Ratings. The stock has a B grade for Value. Within the Biotech industry, IMTX is ranked #76 among the 341 stocks.
In addition to the POWR Ratings we've stated above, we also have IMTX ratings for Quality, Growth, Momentum, Stability, and Sentiment. Get all IMTX ratings <a href="https://stocknews.com/stock/IMTX/">here</a>.
Stock #1: Jazz Pharmaceuticals plc (<a href="https://stocknews.com/stock/JAZZ/">JAZZ</a>)
JAZZ identifies, develops, and commercializes pharmaceutical products for unmet medical needs internationally. The company provides Xywav, Xyrem, Epidiolex, Zepzelca, Rylaze, Enrylaz, Defitelio, and Vyxeos.
JAZZ's trailing-12-month gross profit and EBIT margins of 92.60% and 19.84% are 61.3% and 787.6% higher than the respective industry averages of 57.41% and 2.23%. Likewise, the stock's trailing-12-month levered FCF margin of 27.17% is significantly higher than the industry average of 1.30%.
During the second quarter, which ended June 30, 2024, JAZZ's total revenues increased 6.9% year-over-year to $1.02 billion. Its income from operations grew 26.5% from the year-ago value to $199.44 million. The company's non-GAAP adjusted net income and EPS came in at $364.73 million and $5.30, reflecting growth of 12.2% and 17.5% year-over-year, respectively.
Furthermore, the company's cash and cash equivalents and total assets stood at $1.35 billion and $11.36 billion as of June 30, 2024.
According to the company's full year 2024 financial guidance, JAZZ expects its revenues between $4 billion and $4.10 billion. Its net income is expected to be $1.27 billion - $1.35 billion and $19.20 - $20.30 per share.
Street expects JAZZ's revenue for the third quarter (ending September 2024) to increase 6.6% year-over-year to $1.04 billion. Its EPS for the same quarter is expected to grow 14.2% year-over-year to $5.53. Also, the company has topped the consensus revenue estimates in three of the four trailing quarters.
JAZZ's stock has soared 3.1% over the past month to close the last trading session at $114.29. Wall Street analysts expect the stock to hit $173.76 in the near term, indicating a potential <a href="https://www.tipranks.com/stocks/jazz/forecast">upside of 52%</a>.
JAZZ's POWR Ratings reflect its robust outlook. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
JAZZ has an A grade for Value and Growth. It also has a B grade for Sentiment, and Quality. It is ranked #4 among the 341 stocks in the same industry.
<a href="https://stocknews.com/stock/JAZZ/">Click here</a> to access additional JAZZ ratings for Stability and Momentum.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
JAZZ shares were trading at $114.61 per share on Tuesday afternoon, up $0.32 (+0.28%). Year-to-date, JAZZ has declined -6.82%, versus a 18.91% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/jazz-imtx-pyxs-3-oncology-stocks-with-major-upside/>3 Oncology Stocks With Major Upside</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Oncology Stocks With Major Upside

Leerink Partners analyst Jonathan Chang maintained a Buy rating on Immatics (IMTX – Research Report) on September 8. The company's shares closed ye...

Leerink Partners Remains a Buy on Immatics (IMTX)

Immatics (IMTX) has released an update. Immatics has showcased encouraging initial results from the ongoing Phase 1 trial of its cancer immunothera...

Immatics Reveals Promising IMA401 Trial Results

Biotech bull market is intact as indicated by large cap biopharma and the best performing funds.

Biotech Stocks : Are You A Trader Or A Longer Term Investor?

Immatics (IMTX) has received a new Buy rating, initiated by Piper Sandler analyst, Joseph Catanzaro. Joseph Catanzaro has given his Buy rating due ...

Immatics' Promising Pipeline and Buy Recommendation: A Comprehensive Analysis by Joseph Catanzaro

Immatics (IMTX) has released an update. Immatics has reported promising updated Phase 1b clinical data for its ACTengine IMA203 therapy targeting P...

Immatics Advances IMA203 to Phase 3 Trial in Melanoma

Immatics stock falls as it looks to raise $150M via public offering

ARGX

CRMD

IMTX

JAZZ

NVAX

PYXS

Earnings

Press Releases

Immatics Announces First Quarter 2024 Financial Results and Business Update

Memo Therapeutics AG appoints Paul Carter as Chairperson

Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024

Immatics Appoints Alise Reicin to Board of Directors

Immatics Announces Second Quarter 2024 Financial Results and Business Update

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

Immatics Announces Proposed $150 Million Public Offering

ALDR

IRWD

VECT

AnaptysBio

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Ardelyx

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

ArriVent BioPharma

Bicara Therapeutics

Cogent Biosciences

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Gyre Therapeutics

Disc Medicine

Kura Oncology

Mesoblast Limited - American Depositary Shares

Mesoblast

Oruka Therapeutics

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Relay Therapeutics

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

ARS Pharmaceuticals

Spyre Therapeutics

Travere Therapeutics, Inc. - Common Stock

Comments

Immatics

Noticias

Últimas noticias sobre Immatics (NASDAQ:IMTX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL